Why global pharma is looking at India for scale and science
India is emerging as a powerhouse in the global life sciences landscape. Over the past decade, pharmaceutical companies have steadily moved beyond outsourcing and contract manufacturing to a more strategic model: Global Capability Centers, or GCCs. These centers are no longer just back offices. They are becoming engines of innovation, data science, and regulatory expertise for some of the world’s largest pharma brands.
The shift from support to strategy
In the early 2000s, many multinationals saw India primarily as a cost-saving destination. Teams were set up for routine work such as data entry, regulatory documentation, or finance support. Fast forward to today and the story has changed dramatically.
India’s GCCs for life sciences now handle advanced analytics, clinical trial management, pharmacovigilance, and even early-stage R&D. Global firms are using India as a hub to experiment with AI in drug discovery, automate compliance processes, and support global product launches. The role of Indian GCCs is evolving from support functions to strategic decision-making engines.
Why India is at the center of the boom
Three key factors explain why pharma brands are investing heavily in Indian GCCs:
- Talent at scale: India produces one of the largest pools of life sciences graduates in the world. Combine that with a growing base of data scientists, statisticians, and AI engineers, and you have a rare blend of domain expertise and digital skills.
- Digital infrastructure: With high-speed internet penetration, advanced health data frameworks, and government-backed digital initiatives, India offers a strong ecosystem for data-driven pharma operations.
- Cost efficiency without compromise: GCCs in India can deliver world-class outputs at a fraction of Western costs, freeing up global budgets for innovation and new therapies.
What pharma companies are doing differently in 2025
A wave of multinational pharma and biotech companies are upgrading their India presence:
- Moving up the value chain: Functions like clinical data management and pharmacovigilance are expanding into real-time safety monitoring and predictive analytics.
- Investing in AI and automation: GCCs are building platforms to accelerate clinical trials, optimize supply chains, and improve patient engagement.
- Focusing on compliance and quality: With regulators in the US and Europe becoming stricter, India centers are taking ownership of end-to-end compliance, ensuring global filings meet the highest standards.
Challenges to navigate
Of course, the boom comes with challenges. Talent retention is becoming harder as demand outstrips supply, especially for niche roles in data science and regulatory affairs. Cultural alignment between global headquarters and India teams can also slow decision-making if not managed carefully. Finally, as GCCs take on more strategic roles, they need robust governance models to avoid duplication or siloed efforts.
How to set up successfully
For a pharma company considering an India GCC, success depends on three things:
- Choosing the right city: Hyderabad, Bengaluru, and Pune are strong contenders, each with distinct advantages in life sciences talent, technology ecosystems, and cost.
- Building a hybrid talent pool: Pair scientific expertise with technology skills to unlock the full value of a GCC.
- Investing in culture and compliance: Embedding global values, while staying aligned with Indian regulations, ensures credibility and smooth integration.
The bigger picture
India’s life sciences GCCs are no longer about cost saving. They are about creating value, driving innovation, and shaping the global pharma agenda. For brands that want to stay competitive, ignoring India is not an option.
If you are exploring India for your life sciences operations, Traecit can help you design and execute a GCC strategy that blends regulatory confidence with operational excellence.
Traecit helps global firms build GCCs that deliver scale, efficiency, and innovation from day one.
Visit our website to know more!
